PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Breast cancer is the second leading cause of death for women worldwide. The
heterogeneity of this disease presents a big challenge in its therapeutic management …
heterogeneity of this disease presents a big challenge in its therapeutic management …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
Regulation of PD-L1 expression in the tumor microenvironment
M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …
Hypoxia-driven immune escape in the tumor microenvironment
The tumor microenvironment is a complex ecosystem comprised of many different cell types,
abnormal vasculature and immunosuppressive cytokines. The irregular growth kinetics with …
abnormal vasculature and immunosuppressive cytokines. The irregular growth kinetics with …
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
SE Stanton, ML Disis - Journal for immunotherapy of cancer, 2016 - Springer
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …
The landscape of targeted therapies in TNBC
E Vagia, D Mahalingam, M Cristofanilli - Cancers, 2020 - mdpi.com
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
[HTML][HTML] The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment
K Hudson, N Cross, N Jordan-Mahy… - Frontiers in …, 2020 - frontiersin.org
Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …
Recent advances in triple negative breast cancer: the immunotherapy era
Background Several accomplishments have been achieved in triple-negative breast cancer
(TNBC) research over the last year. The phase III IMpassion130 trial comparing …
(TNBC) research over the last year. The phase III IMpassion130 trial comparing …